Hepatology

September 19th 2024

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

September 19th 2024

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

September 19th 2024

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

September 16th 2024

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.